Inhaled Messenger RNA Treatment Fast-Tracked for Cystic Fibrosis
The Food and Drug Administration has granted Fast Track designation to MRT5005 (Translate Bio), an inhaled messenger RNA (mRNA)...
COVID-19 in Chronic Lung Disease: What You Need to Know
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and novel coronavirus disease (COVID-19) have been of major concern to the...
This new treatment helps 90% of cystic fibrosis patients breathe better
Vertex’s Trikafta was the second-fastest FDA approval in history, and could help some 27,000 patients. In October 2019, Vertex...
CFTR Amplifiers May Be Potent CF Mono or Combo Therapy, Study Says
Amplifiers, a potential new class of therapies that modify CFTR — the protein whose defects cause cystic fibrosis (CF) — do so by...
UK NICE to Announce Decision on Vertex’s Therapy Trikafta in December
The National Institute for Health and Care Excellence (NICE) in the U.K. is currently in the process of evaluating Vertex...
FDA Grants Fast Track Status to Translate Bio’s RNA-Based Therapy MRT5005
The U.S. Food and Drug Administration (FDA) has granted fast track designation to MRT5005, an investigational RNA-based treatment for...